A story that has - until now - gone unremarked is that a Munich-based single family office controls the firm that has worked with Pfizer and developed a vaccine candidate for dealing with COVID-19. Using exclusive data from Highworth Research, we calculate how this has transformed the family office's fortunes. On 9 November Pfizer, the multinational US pharmaceutical company and BioNTech, a German immunotherapy company based in Mainz and listed on Nasdaq, issued a bombshell.